Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 2/20 | 0.41 |
| ▸ | DDR1 | Q08345 | 5/20 | 0.39 |
| ▸ | SCN1A | P35498 | 2/20 | 0.38 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.38 |
| ▸ | LTA4H | P09960 | 1/20 | 0.38 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.38 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | MELK | Q14680 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | FPR2 | P25090 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13699609 | 1.00 | MDM2 (0.41) | MDM2DDR1SCN1ASCN8ALTA4H | |
| SCHEMBL13699648 | 0.88 | MDM2 (0.41) | MDM2DDR1SCN1ASCN8ALTA4H | |
| SCHEMBL13699606 | 0.87 | LTA4H (0.41) | MDM2DDR1SCN1ASCN8ALTA4H | |
| SCHEMBL13699607 | 0.87 | LTA4H (0.41) | MDM2DDR1SCN1ASCN8ALTA4H | |
| SCHEMBL13699596 | 0.84 | MDM2 (0.44) | MDM2DDR1KCNH2 | |
| SCHEMBL13699581 | 0.84 | MLNR (0.47) | MDM2KCNH2 | |
| SCHEMBL13699584 | 0.84 | MLNR (0.47) | MDM2KCNH2 | |
| SCHEMBL13699599 | 0.84 | MDM2 (0.43) | MDM2 | |
| SCHEMBL13699585 | 0.84 | MLNR (0.46) | MDM2 | |
| SCHEMBL4167196 | 0.82 | MDM2 (0.47) | MDM2PDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | VERNALIS (R&D) (GB) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221582-A1 | Piperazine Derivatives And Their Use In Therapy | CNR2, CNR1, ALK | MDM2 2997/4885DDR1 2738/4885SCN1A 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.